Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $334 Million - $447 Million
-3,810,246 Reduced 50.0%
3,810,248 $371 Million
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $2.33 Million - $2.67 Million
31,200 Added 0.41%
7,620,494 $589 Million
Q4 2018

Feb 13, 2019

BUY
$80.14 - $106.07 $497,669 - $658,694
6,210 Added 0.08%
7,589,294 $646 Million
Q4 2017

Feb 14, 2018

BUY
$80.76 - $95.13 $135 Million - $160 Million
1,677,411 Added 28.4%
7,583,084 $676 Million
Q3 2017

Nov 14, 2017

BUY
$80.6 - $94.95 $476 Million - $561 Million
5,905,673
5,905,673 $550 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.